Fig. 1From: Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort studyKaplan Meier survival curves of overall survival (RAS/BRAFV600E wild-type; RAS or BRAF.V600E mutant)Back to article page